Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REPREVIO vedolizumab postoperative recurrence prevention trial in Crohn's disease
NL-OMON55604Phase 4Active, not recruiting
- Sponsor
- Amsterdam University Medical Center
- Start
- Jan 2017
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in Crohn's disease comparing Vedolizumab with Placebo (2 arms). Started Jan 2017; status: active, not recruiting.
02
Drugs
vedolizumab
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on NL-OMON55604.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON55604.